PH12018501335A1 - Novel generation of antigen-specific tcrs - Google Patents

Novel generation of antigen-specific tcrs

Info

Publication number: PH12018501335A1
Authority: PH; Philippines
Prior art keywords: antigen; specific; mhc class; generation; lymphocytes
Prior art date: 2015-12-23

Application number

PH12018501335A

Other languages

English (en)

Inventor

Slavoljub Milosevic

Christian Ellinger

Carina Wehner

Dolores Schendel

Original Assignee

Medigene Immunotherapies Gmbh

Helmholtz Zentrum Munchen Deutsches Forschungszentrum Fur Gesundheit Und Umwelt Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-12-23

Filing date

2018-06-21

Publication date

2019-02-18

2018-06-21 Application filed by Medigene Immunotherapies Gmbh, Helmholtz Zentrum Munchen Deutsches Forschungszentrum Fur Gesundheit Und Umwelt Gmbh filed Critical Medigene Immunotherapies Gmbh

2019-02-18 Publication of PH12018501335A1 publication Critical patent/PH12018501335A1/en

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4268—MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4269—NY-ESO
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4271—Melanoma antigens
- A61K40/4272—Melan-A/MART
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1114—T cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
- C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Pharmacology & Pharmacy (AREA)
Microbiology (AREA)
Hematology (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Toxicology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Oncology (AREA)
Mycology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Developmental Biology & Embryology (AREA)

PH12018501335A 2015-12-23 2018-06-21 Novel generation of antigen-specific tcrs PH12018501335A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP15202329		2015-12-23
EP16190399		2016-09-23
PCT/EP2016/082443 WO2017109109A1 (en)	2015-12-23	2016-12-22	Novel generation of antigen-specific tcrs

Publications (1)

Publication Number	Publication Date
PH12018501335A1 true PH12018501335A1 (en)	2019-02-18

Family

ID=57794260

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PH12018501335A PH12018501335A1 (en)	2015-12-23	2018-06-21	Novel generation of antigen-specific tcrs
PH12018501336A PH12018501336A1 (en)	2015-12-23	2018-06-21	Dendritic cell composition

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PH12018501336A PH12018501336A1 (en)	2015-12-23	2018-06-21	Dendritic cell composition

Country Status (17)

Country	Link
US (2)	US11155589B2 (ja)
EP (4)	EP3901254A1 (ja)
JP (3)	JP6676759B2 (ja)
KR (4)	KR20180093954A (ja)
CN (2)	CN108603171A (ja)
AU (2)	AU2016374874B2 (ja)
BR (2)	BR112018012694A2 (ja)
CA (2)	CA3009564C (ja)
DK (2)	DK3394247T3 (ja)
EA (2)	EA201891460A1 (ja)
ES (2)	ES2863733T3 (ja)
HU (1)	HUE053674T2 (ja)
MX (2)	MX2018007842A (ja)
PH (2)	PH12018501335A1 (ja)
PL (2)	PL3394247T3 (ja)
TW (2)	TWI772282B (ja)
WO (2)	WO2017109110A1 (ja)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2016273214B2 (en)	2015-06-01	2018-10-18	Medigene Immunotherapies Gmbh	Method for generating antibodies against T cell receptor
HK1253694A1 (zh)	2015-06-01	2019-06-28	Medigene Immunotherapies Gmbh	T細胞受體文庫
CN108603171A (zh)	2015-12-23	2018-09-28	基因医疗免疫疗法有限责任公司	新一代抗原-特异性tcr
SG11202005236QA (en) *	2017-12-04	2020-07-29	The United States Of America As Represented By The Secretary	Hla class i-restricted t cell receptors against mutated ras
US10808465B2 (en) *	2018-04-27	2020-10-20	Canrig Robotic Technologies As	System and method for conducting subterranean operations
US11015402B2 (en)	2018-04-27	2021-05-25	Canrig Robotic Technologies As	System and method for conducting subterranean operations
CA3100931A1 (en) *	2018-06-21	2019-12-26	Universiteit Gent	Method for the in vitro differentiation and maturation of dendritic cells for therapeutic use
CN110172091B (zh) *	2019-04-28	2020-04-03	天津亨佳生物科技发展有限公司	一种针对egfr l858r基因突变的特异性t细胞受体及其应用
JP2022535045A (ja) *	2019-06-03	2022-08-04	ザスクリプスリサーチインスティテュート	細胞間近接相互作用の検出および免疫療法用の腫瘍特異的抗原反応性ｔ細胞の単離のための化学酵素的方法
US20230338530A1 (en) *	2020-01-10	2023-10-26	Lg Chem, Ltd.	Composition comprising antigen-presenting cell co-expressing mhc and tumor antigen, and cancer treatment using same
CN112133372B (zh) *	2020-08-18	2022-06-03	北京臻知医学科技有限责任公司	抗原特异性tcr数据库的建立方法及抗原特异性tcr的评估方法
WO2022086185A1 (ko) *	2020-10-20	2022-04-28	연세대학교 산학협력단	단일 세포 분석법을 이용한 tcr-항원의 특이성을 확인하는 방법
WO2022115415A1 (en) *	2020-11-24	2022-06-02	Providence Health & Services - Oregon	T cell receptors specific for a mutant form of the ret oncogene and uses thereof
WO2023060163A2 (en) *	2021-10-06	2023-04-13	Board Of Regents, The University Of Texas System	Shp1 modified dendritic cells and extracellular vesicles derived therefrom and associated methods
TW202340474A (zh) *	2022-01-11	2023-10-16	大陸商深圳市珈鈺生物科技有限公司	樹突細胞腫瘤疫苗和其用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4703004A (en)	1984-01-24	1987-10-27	Immunex Corporation	Synthesis of protein with an identification peptide
US4851341A (en)	1986-12-19	1989-07-25	Immunex Corporation	Immunoaffinity purification system
US5766947A (en)	1988-12-14	1998-06-16	Astra Ab	Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
JPH05504621A (ja)	1989-11-15	1993-07-15	ナショナル・ジューイッシュ・センター・フォア・イミュノロジー・アンド・レスピラトリー・メディスン	ヒトｔ細胞表面抗原の定量法
WO1992002629A1 (en)	1990-08-09	1992-02-20	National Jewish Center For Immunology And Respiratory Medicine	Producing monoclonal antibodies against human t-cell receptor elements using recombinant dna vectors
US5871732A (en)	1990-11-27	1999-02-16	Biogen, Inc.	Anti-CD4 antibody homologs useful in prophylaxis and treatment of AIDS, ARC and HIV infection
US5480895A (en)	1991-09-27	1996-01-02	New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery	Method of producing antibodies to a restricted population of T lymphocytes, antibodies produced therefrom and methods of use thereof
CA2122732C (en)	1991-11-25	2008-04-08	Marc D. Whitlow	Multivalent antigen-binding proteins
CA2507749C (en)	1991-12-13	2010-08-24	Xoma Corporation	Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
NZ255831A (en)	1992-08-21	1997-04-24	Biogen Inc	Fusion proteins comprising biologically active cargo moiety and transport peptides from the hiv tat protein, their preparation and use
US6372716B1 (en)	1994-04-26	2002-04-16	Genetics Institute, Inc.	Formulations for factor IX
US6685940B2 (en)	1995-07-27	2004-02-03	Genentech, Inc.	Protein formulation
DE19625191A1 (de)	1996-06-24	1998-01-02	Boehringer Mannheim Gmbh	Nierenkarzinom-spezifische T-Zellen
US6284879B1 (en) *	1998-04-16	2001-09-04	The General Hospital Corporation	Transport associated protein splice variants
US6566329B1 (en)	1999-06-28	2003-05-20	Novo Nordisk A/S	Freeze-dried preparation of human growth hormone
US20050112141A1 (en) *	2000-08-30	2005-05-26	Terman David S.	Compositions and methods for treatment of neoplastic disease
EP1118661A1 (en)	2000-01-13	2001-07-25	Het Nederlands Kanker Instituut	T cell receptor libraries
AU2001232204A1 (en)	2000-02-22	2001-09-03	Ahuva Nissim	Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof
EP2278023A1 (en) *	2000-04-28	2011-01-26	Mannkind Corporation	Epitope cluster from Melan-A/MART-1 for the induction of anti-tumor immunogenicity
IL136459A0 (en)	2000-05-30	2001-06-14	Galim Galil Immunology Ltd	Antibody library
US7829084B2 (en)	2001-01-17	2010-11-09	Trubion Pharmaceuticals, Inc.	Binding constructs and methods for use thereof
FR2822846B1 (fr)	2001-04-03	2004-01-23	Technopharm	Procede de preparation et de selection d'anticorps
WO2003025020A1 (fr)	2001-09-13	2003-03-27	Institute For Antibodies Co., Ltd.	Procede pour creer une banque d'anticorps de chameaux
NZ570811A (en)	2002-11-09	2009-11-27	Immunocore Ltd	T cell receptor display
GB0411773D0 (en)	2004-05-26	2004-06-30	Avidex Ltd	Method for the identification of polypeptides which bind to a given peptide mhc complex or cd 1-antigen complex
GB0411771D0 (en)	2004-05-26	2004-06-30	Avidex Ltd	Nucleoproteins displaying native T cell receptor libraries
ES2672895T3 (es)	2005-08-05	2018-06-18	Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh	Generación de células T específicas de antígeno
JP2007097580A (ja)	2005-09-06	2007-04-19	Shizuoka Prefecture	Ｔ細胞レセプターβ鎖遺伝子
EP1840206A1 (en) *	2006-03-28	2007-10-03	Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh	Compositions for the preparation of mature dendritic cells
US20090304657A1 (en)	2006-05-03	2009-12-10	The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services	Chimeric t cell receptors and related materials and methods of use
US20100247430A1 (en) *	2007-08-30	2010-09-30	Andrew Chan	Methods and Compositions for Modulating T Cells
US20130108663A1 (en) *	2007-09-14	2013-05-02	Vrije Universiteit Brussel	Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination
US8394778B1 (en) *	2009-10-08	2013-03-12	Immune Disease Institute, Inc.	Regulators of NFAT and/or store-operated calcium entry
WO2011053789A2 (en) *	2009-10-30	2011-05-05	James Cameron Oliver	Pharmaceutical composition and methods to enhance cytotoxic t-cell recognition and maintain t-cell memory against a pathogenic disease
BR112012020588A2 (pt)	2010-03-02	2015-09-15	Hoffmann La Roche	"vetor de expressão de ácido nucleido, célula, método para geração de anticorpos monoclonais e invenção"
CN102719399A (zh) *	2012-04-28	2012-10-10	北京爱根生物科技有限公司	自体特异性t细胞的体外扩增方法及所制备的t细胞体系、体系的药物应用和组分监测方法
SI2861240T1 (sl)	2012-06-15	2021-04-30	Immunomic Therapeutics, Inc.	Nukleinske kisline za zdravljenje alergij
TW201425336A (zh)	2012-12-07	2014-07-01	Amgen Inc	Ｂｃｍａ抗原結合蛋白質
MX375919B (es)	2014-03-14	2025-03-07	Immunocore Ltd	Bibliotecas de tcr.
WO2016057986A1 (en)	2014-10-10	2016-04-14	The Trustees Of Columbia University In The City Of New York	Tandem epitope constructs for presentation of cd4 and cd8 epitopes and uses thereof
HK1253694A1 (zh)	2015-06-01	2019-06-28	Medigene Immunotherapies Gmbh	T細胞受體文庫
CA2987877A1 (en)	2015-06-01	2016-12-08	Medigene Immunotherapies Gmbh	T-cell receptor specific antibodies
AU2016273214B2 (en)	2015-06-01	2018-10-18	Medigene Immunotherapies Gmbh	Method for generating antibodies against T cell receptor
CN108603171A (zh)	2015-12-23	2018-09-28	基因医疗免疫疗法有限责任公司	新一代抗原-特异性tcr

2016
- 2016-12-22 CN CN201680075559.8A patent/CN108603171A/zh active Pending
- 2016-12-22 EA EA201891460A patent/EA201891460A1/ru unknown
- 2016-12-22 US US16/065,024 patent/US11155589B2/en active Active
- 2016-12-22 DK DK16825764.0T patent/DK3394247T3/da active
- 2016-12-22 TW TW105142799A patent/TWI772282B/zh not_active IP Right Cessation
- 2016-12-22 BR BR112018012694A patent/BR112018012694A2/pt not_active Application Discontinuation
- 2016-12-22 WO PCT/EP2016/082445 patent/WO2017109110A1/en not_active Application Discontinuation
- 2016-12-22 US US16/065,037 patent/US10882891B2/en not_active Expired - Fee Related
- 2016-12-22 MX MX2018007842A patent/MX2018007842A/es unknown
- 2016-12-22 WO PCT/EP2016/082443 patent/WO2017109109A1/en active Application Filing
- 2016-12-22 KR KR1020187017846A patent/KR20180093954A/ko not_active Ceased
- 2016-12-22 ES ES16825764T patent/ES2863733T3/es active Active
- 2016-12-22 JP JP2018533099A patent/JP6676759B2/ja active Active
- 2016-12-22 PL PL16825764T patent/PL3394247T3/pl unknown
- 2016-12-22 EP EP21155874.7A patent/EP3901254A1/en active Pending
- 2016-12-22 EP EP16825765.7A patent/EP3394248B1/en active Active
- 2016-12-22 PL PL16825765T patent/PL3394248T3/pl unknown
- 2016-12-22 AU AU2016374874A patent/AU2016374874B2/en not_active Ceased
- 2016-12-22 ES ES16825765T patent/ES2865484T3/es active Active
- 2016-12-22 EP EP16825764.0A patent/EP3394247B1/en active Active
- 2016-12-22 CA CA3009564A patent/CA3009564C/en active Active
- 2016-12-22 DK DK16825765.7T patent/DK3394248T3/da active
- 2016-12-22 BR BR112018012826A patent/BR112018012826A2/pt not_active Application Discontinuation
- 2016-12-22 CA CA3009542A patent/CA3009542C/en active Active
- 2016-12-22 KR KR1020207023474A patent/KR20200100858A/ko not_active Withdrawn
- 2016-12-22 JP JP2018533086A patent/JP6697562B2/ja not_active Expired - Fee Related
- 2016-12-22 TW TW105142798A patent/TWI752930B/zh active
- 2016-12-22 CN CN201680075578.0A patent/CN108473960A/zh active Pending
- 2016-12-22 AU AU2016374873A patent/AU2016374873B2/en active Active
- 2016-12-22 HU HUE16825764A patent/HUE053674T2/hu unknown
- 2016-12-22 KR KR1020207019363A patent/KR102319839B1/ko active Active
- 2016-12-22 EA EA201891459A patent/EA201891459A1/ru unknown
- 2016-12-22 KR KR1020187017847A patent/KR20180089446A/ko not_active Ceased
- 2016-12-22 MX MX2018007841A patent/MX2018007841A/es unknown
- 2016-12-22 EP EP21155881.2A patent/EP3889253A1/en not_active Withdrawn
2018
- 2018-06-21 PH PH12018501335A patent/PH12018501335A1/en unknown
- 2018-06-21 PH PH12018501336A patent/PH12018501336A1/en unknown
2020
- 2020-03-12 JP JP2020042812A patent/JP2020114222A/ja active Pending

Also Published As

Publication number	Publication date
PL3394248T3 (pl)	2021-09-13
US20190002515A1 (en)	2019-01-03
AU2016374873A1 (en)	2018-05-17
ES2865484T3 (es)	2021-10-15
DK3394247T3 (da)	2021-04-12
NZ741954A (en)	2020-04-24
CA3009542A1 (en)	2017-06-29
EA201891460A1 (ru)	2018-12-28
JP6676759B2 (ja)	2020-04-08
EP3394247B1 (en)	2021-02-10
PH12018501336A1 (en)	2019-02-18
MX2018007842A (es)	2018-11-09
HUE053674T2 (hu)	2021-07-28
EA201891459A1 (ru)	2018-11-30
JP2018538001A (ja)	2018-12-27
CN108603171A (zh)	2018-09-28
TW201736594A (zh)	2017-10-16
US20190000949A1 (en)	2019-01-03
PL3394247T3 (pl)	2021-08-23
CA3009564C (en)	2023-08-29
KR20200085362A (ko)	2020-07-14
JP2018537999A (ja)	2018-12-27
BR112018012694A2 (pt)	2018-12-04
EP3394247A1 (en)	2018-10-31
TWI772282B (zh)	2022-08-01
ES2863733T3 (es)	2021-10-11
TW201736595A (zh)	2017-10-16
MX2018007841A (es)	2018-11-09
KR102319839B1 (ko)	2021-11-01
CN108473960A (zh)	2018-08-31
EP3901254A1 (en)	2021-10-27
CA3009542C (en)	2023-08-29
TWI752930B (zh)	2022-01-21
DK3394248T3 (da)	2021-04-19
NZ741955A (en)	2020-04-24
AU2016374874A1 (en)	2018-05-17
KR20200100858A (ko)	2020-08-26
US11155589B2 (en)	2021-10-26
BR112018012826A2 (pt)	2018-12-04
CA3009564A1 (en)	2017-06-29
EP3889253A1 (en)	2021-10-06
JP2020114222A (ja)	2020-07-30
JP6697562B2 (ja)	2020-05-20
AU2016374873B2 (en)	2020-12-24
WO2017109110A1 (en)	2017-06-29
AU2016374874B2 (en)	2020-12-03
US10882891B2 (en)	2021-01-05
EP3394248A1 (en)	2018-10-31
WO2017109109A1 (en)	2017-06-29
KR20180089446A (ko)	2018-08-08
KR20180093954A (ko)	2018-08-22
EP3394248B1 (en)	2021-02-10

Publication	Publication Date	Title
PH12018501335A1 (en)	2019-02-18	Novel generation of antigen-specific tcrs
PH12018502601A1 (en)	2019-09-30	Anti-b7-h3 antibodies and antibody drug conjugates
MX2019006045A (es)	2019-11-11	Proteinas triespecificas dirigidas a psma y metodos de uso.
MX395287B (es)	2025-03-25	Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos.
CL2020001181A1 (es)	2020-08-21	Nuevos receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos.
ZA201905822B (en)	2024-01-31	Antibodies against pd-l1
CL2019001535A1 (es)	2019-10-11	Nuevos receptores de células t y terapia inmunológica que los utiliza.
AR115389A1 (es)	2021-01-13	Anticuerpo antagonista de cd73
WO2018098365A3 (en)	2018-07-12	Compositions and methods for tcr reprogramming using fusion proteins
MX2024005678A (es)	2024-06-11	Receptores de celulas t que reconocen p53 mutado.
CY1122612T1 (el)	2021-03-12	Μεθοδος
MX2022000012A (es)	2022-05-20	Prediccion de epitopos de celulas t utiles para vacunacion.
EA201792420A1 (ru)	2018-04-30	Композиции и способы перепрограммирования tcr с помощью гибридных белков
MX2018015277A (es)	2019-09-06	Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MX2018015285A (es)	2019-09-18	Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MX2020010035A (es)	2020-10-14	Receptores de celulas t anti-papilomavirus 16 e7 humano.
MX2022007902A (es)	2022-07-21	Metodos para predecir la utilidad de proteinas o fragmentos de proteina para inmunoterapia.
MX2017014397A (es)	2018-04-11	Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn).
MX2023010640A (es)	2024-02-07	Péptidos neoantigénicos transmembranales.
CY1122644T1 (el)	2021-03-12	Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων
PH12018500159A1 (en)	2018-07-23	Constructs targeting psa peptide/mhc complexes and uses thereof
CR20210094A (es)	2021-03-31	ANTICUERPOS QUE SE UNEN A LA PROTEÍNA DE ENVOLTURA DEL VIRUS ZIKA Y USOS DE LOS MISMOS (Divisional 2019-0193)
MX2019007924A (es)	2020-01-27	Vacunas contra la influenza.
TR201901466T4 (tr)	2019-02-21	Opti̇mi̇ze edi̇lmi̇ş feli̇n lösemi̇ vi̇rüsü zarf geni̇ni̇ i̇çeren rekombi̇nant feli̇n lösemi̇ vi̇rüsü
MX2013013812A (es)	2014-05-28	Vacunas geneticas contra el virus hendra y el virus nipah.